27 active not recruiting. 27 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 27 | Active not recruiting 27 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Blood Coagulation Disorders: new trials by email Literature Review of Blood Coagulation Disorders trials Research Report on Blood Coagulation Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment. FRSW107 - Severe Hemophilia A | Phase 3 | Active not recruiting | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 60 | 2026-06-12 | 2026-09-04 |
| Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment FRSW107 - Severe Hemophilia A | Phase 3 | Active not recruiting | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 60 | 2026-04-14 | 2026-09-08 |
| Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan rilzabrutinib - Immune Thrombocytopenia | Phase 3 | Active not recruiting | Sanofi | 4 | 2025-10-15 | 2025-11-06 |
| Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A Switching to low dose emicizumab - Hemophilia A Patient | Phase 2 / Phase 3 | Active not recruiting | Chulalongkorn University | 18 | 2025-06-01 | 2026-02-27 |
| Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients STSP-0601 for Injection - Hemophilia | Phase 3 | Active not recruiting | Jiangsu BioJeTay Biotechnology Co., Ltd. | 40 | 2025-03-26 | 2026-08-12 |
| Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa Efanesoctocog alfa - Haemophilia A (Moderate or Severe) | Phase 3 | Active not recruiting | Swedish Orphan Biovitrum | 89 | 2025-03-06 | 2026-10-19 |
| A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A Recombinant human activated coagulation factor VIII for injection - Hemophilia A | Phase 3 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 60 | 2024-11-12 | 2026-06-12 |
| Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) Bomedemstat, Hydroxyurea, Bomedemstat placebo - Essential Thrombocythemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 300 | 2024-07-16 | 2026-08-27 |
| A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) Bomedemstat, Anagrelide, Busulfan - Essential Thrombocythemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 340 | 2023-12-31 | 2026-10-02 |
| Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A Valoctocogene roxaparvovec - Hemophilia A | Phase 3 | Active not recruiting | BioMarin Pharmaceutical | 6 | 2023-12-25 | 2026-03-19 |
| A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients Ropeginterferon alfa-2b (BESREMi®) - Essential Thrombocythaemia | Phase 3 | Active not recruiting | AOP Orphan Pharmaceuticals AG | 117 | 2023-12-04 | 2024-12-19 |
| A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A Mim8 - Haemophilia A, Haemophilia A With Inhibitors | Phase 3 | Active not recruiting | Novo Nordisk A/S | 451 | 2023-02-13 | 2026-09-09 |
| Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) Ianalumab, Placebo, Corticosteroids - Primary Immune Thrombocytopenia (ITP) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 226 | 2023-02-03 | 2026-06-15 |
| A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids Ianalumab, Eltrombopag, Placebo - Primary Immune Thrombocytopenia | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 152 | 2023-02-02 | 2026-08-21 |
| A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC) - Hemophilia | Phase 3 | Active not recruiting | Sanofi | 91 | 2023-02-01 | 2026-02-04 |
| Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia romiplostim plus dexamethasone, Dexamethasone - Primary Immune Thrombocytopenia | Phase 3 | Active not recruiting | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 129 | 2022-12-02 | 2025-06-17 |
| A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101) - Polycythemia Vera | Phase 3 | Active not recruiting | PharmaEssentia | 111 | 2022-10-26 | 2025-08-13 |
| A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors Concizumab - Haemophilia A and B With and Without Inhibitors | Phase 3 | Active not recruiting | Novo Nordisk A/S | 153 | 2022-03-24 | 2026-09-18 |
| Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug Single dose intravenous injection of BBM-H901 - Hemophilia B | Phase 2 / Phase 3 | Active not recruiting | Shanghai Xinzhi BioMed Co., Ltd. | 32 | 2021-12-30 | 2026-04-01 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia efgartigimod PH20 SC - Primary Immune Thrombocytopenia | Phase 3 | Active not recruiting | argenx | 173 | 2021-11-17 | 2026-10-19 |
Showing 20 of 27. Sign in to see all of them.
Hemophilia A (14) · Purpura, Thrombocytopenic, Idiopathic (5) · Thrombocythemia, Essential (5) · Coagulation Protein Disorders (2) · Hematologic Diseases (2) · Hemophilia B (2) · Blood Coagulation Disorders, Inherited (1) · Genetic Diseases, Inborn (1) · Hemarthrosis (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Lymphoma, Follicular (1) · Myeloproliferative Disorders (1) · Polycythemia (1)
Hemic and Lymphatic Diseases (27) · Hematologic Diseases (25) · Hemorrhagic Disorders (25) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (16) · Blood Coagulation Disorders, Inherited (15) · Genetic Diseases, Inborn (15) · Coagulation Protein Disorders (13) · Blood Platelet Disorders (11) · Cytopenia (7) · Hemorrhage (7) · Immune System Diseases (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Purpura (6)
BIVV001 (2) · Injections (2) · anagrelide (2) · bomedemstat (2) · emicizumab (2) · ianalumab (2) · ADAMTS13 protein, human (1) · Adrenal Cortex Hormones (1) · Busulfan (1) · Dexamethasone (1) · Genetic Therapy (1) · Hydroxyurea (1) · Valoctocogene Roxaparvovec (1) · concizumab (1) · eltrombopag (1)
Hangzhou Gensciences Biopharmaceutical Co., Ltd. (2) · Merck Sharp & Dohme LLC (2) · Novartis Pharmaceuticals (2) · Novo Nordisk A/S (2) · Pfizer (2) · PharmaEssentia (2) · Sanofi (2) · AOP Orphan Pharmaceuticals AG (1) · BioMarin Pharmaceutical (1) · Bioverativ, a Sanofi company (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1) · Chulalongkorn University (1) · Fondazione Telethon (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Hoffmann-La Roche (1)
Italy (17) · United States (16) · China (15) · Japan (15) · Spain (15) · France (14) · United Kingdom (13) · Germany (12) · Turkey (Türkiye) (12) · Canada (11) · South Korea (9) · Taiwan (9) · Australia (8) · Greece (8) · Poland (8)
Renchi Yang, PhD (2) · Caifeng Yang, Master (1) · Charlotte Bradbury (1) · Craig Zimmerman, PhD (1) · Lei Zhang, MD (1) · Lei Zhang, Ph.D (1)
PMID 34435432, PMID 35924546, PMID 36636993, PMID 38127586, PMID 38446574, PMID 39321362, PMID 39585605, PMID 40441148, PMID 40750723, PMID 41180128, PMID 41193116, PMID 41266685, PMID 41363800, PMID 42469164, PMID 42777242
2023 (5), 2018 (1)